← Back to Search

Antiplatelet Agent

Oral Blood Thinners for Hip Fracture (HIP PRO Pilot Trial)

Phase 3
Waitlist Available
Led By Prism S Schneider, MD, PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients aged 50 years or older with an acute hip fracture (presentation to hospital within 24 hours of injury) that requires surgical treatment
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

HIP PRO Pilot Trial Summary

This trial will compare different oral blood thinning medications to find the safest + most effective treatment to prevent blood clots after hip fracture surgery. It will benefit patients with hip fractures worldwide.

Who is the study for?
This trial is for adults aged 50 or older who have a hip fracture that needs surgery and got to the hospital within 24 hours of injury. They can be on low-dose anti-platelet therapy like aspirin. People with cancer-related fractures, those who can't follow up, took lots of blood thinners post-injury, or have certain bleeding/clotting disorders can't join.Check my eligibility
What is being tested?
The study compares oral blood thinners Rivaroxaban (10mg) and ASA (81mg) in preventing blood clots after hip fracture surgery. It aims to find out which one is safer and more effective using TEG technology to monitor clotting ability.See study design
What are the potential side effects?
Possible side effects include bleeding risks, allergic reactions to the medications, potential gastrointestinal issues with ASA use such as ulcers, and kidney problems if there's pre-existing renal failure.

HIP PRO Pilot Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 50 or older and need surgery for a hip fracture that happened within the last day.

HIP PRO Pilot Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recruitment Rate
Secondary outcome measures
Arterial thromboembolism events
Bleeding complications
Complete Blood Counts
+12 more

HIP PRO Pilot Trial Design

2Treatment groups
Experimental Treatment
Group I: acetylsalicylic acid (ASA) 81mg dailyExperimental Treatment1 Intervention
acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
Group II: Rivaroxaban 10mgExperimental Treatment1 Intervention
Rivaroxaban 10mg daily for 35 days post hip fracture surgery

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
786 Previous Clinical Trials
846,034 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,336 Previous Clinical Trials
25,750,760 Total Patients Enrolled
Prism S Schneider, MD, PhDPrincipal InvestigatorUniversity of Calgary

Media Library

Acetylsalicylic acid (ASA) 81mg Oral Tablet (Antiplatelet Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05775965 — Phase 3
Hip Fracture Research Study Groups: Rivaroxaban 10mg, acetylsalicylic acid (ASA) 81mg daily
Hip Fracture Clinical Trial 2023: Acetylsalicylic acid (ASA) 81mg Oral Tablet Highlights & Side Effects. Trial Name: NCT05775965 — Phase 3
Acetylsalicylic acid (ASA) 81mg Oral Tablet (Antiplatelet Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05775965 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of safety profile can be expected from taking ten milligrams of Rivaroxaban?

"Previous clinical studies have vouched for the safety of Rivaroxaban 10mg, thus it receives a score of 3 on our ratings board."

Answered by AI

Are enrollment opportunities currently available for this research study?

"As revealed by the clinicaltrials.gov website, this study is no longer actively recruiting. Initially posted on March 1st 2023 and last updated on 7th of the same month, it has concluded its search for participants; however, there are currently 379 other trials looking to enrol patients at present."

Answered by AI
~119 spots leftby Mar 2025